TSE:GUD - Knight Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$8.15 +0.03 (+0.37 %)
(As of 10/21/2018 03:53 PM ET)
Previous CloseC$8.15
Today's RangeC$8.08 - C$8.19
52-Week RangeC$7.38 - C$8.81
Volume109,000 shs
Average Volume133,959 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; PHOTOFRIN for oesophageal and endobronchial cancer, high-grade dysplasia in Barrett's oesophagus, and papillary bladder cancer; ATryn to prevent thromboembolic events; Ember family to treat osteoarthritis, chronic kidney diseases, alport syndrome, and metabolic diseases; and blood factor products. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; dermo-cosmetic line of products, such as Crescita family, Laboratoire Dr. Renaud, Premiology, and Pro-Derm; SEQuaderma, an active dermatology solution; HandMD skin care products; and UrgentRx, a fast-acting, portable over-the-counter medication. Further, the company develops TULSA-PRO, a medical device for prostate ablation; and 3D family diagnostic and prognostic products for cancers and neurological disorders. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.

Receive GUD News and Ratings via Email

Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolTSE:GUD
CUSIPN/A
Phone514-484-4483

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees27
Outstanding Shares142,825,000
Market CapC$0.00

Knight Therapeutics (TSE:GUD) Frequently Asked Questions

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc (TSE:GUD) announced its earnings results on Thursday, August, 9th. The company reported $0.03 earnings per share for the quarter, meeting analysts' consensus estimates of $0.03. The company earned $2.24 million during the quarter, compared to analysts' expectations of $2.38 million. View Knight Therapeutics' Earnings History.

When is Knight Therapeutics' next earnings date?

Knight Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Knight Therapeutics.

What price target have analysts set for GUD?

5 analysts have issued 12 month target prices for Knight Therapeutics' shares. Their forecasts range from C$9.50 to C$10.50. On average, they anticipate Knight Therapeutics' share price to reach C$10.15 in the next year. This suggests a possible upside of 24.5% from the stock's current price. View Analyst Price Targets for Knight Therapeutics.

What is the consensus analysts' recommendation for Knight Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics.

Who are some of Knight Therapeutics' key competitors?

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the folowing people:
  • Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 49)
  • Ms. Samira Sakhia C.A., BCom, MBA, CPA, DPA, CA, Pres, CFO & Director (Age 49)
  • Mr. Michel Loustric, Pres of Knight Barbados
  • Ms. Amal Khouri, VP of Bus. Devel.
  • Ms. Jody Engel, Director of Bus. Devel.

How do I buy shares of Knight Therapeutics?

Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$8.15.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is http://www.gud-knight.com.

How can I contact Knight Therapeutics?

The company can be reached via phone at 514-484-4483.


MarketBeat Community Rating for Knight Therapeutics (TSE GUD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel